Status:
COMPLETED
NovoLet® Surveillance Study on Using Human Insulin System in Indonesia
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this study is to investigate the safety and efficacy of NovoLet® human insulin delivery system in an outpatient setting.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
- Other types of diabetes mellitus (gestational, drug induced \[thiazide\] or metabolic syndrome-related)
Exclusion
Key Trial Info
Start Date :
February 11 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 5 2006
Estimated Enrollment :
1981 Patients enrolled
Trial Details
Trial ID
NCT01492153
Start Date
February 11 2003
End Date
September 5 2006
Last Update
February 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Jakarta, Indonesia, 12520